US FDA approves Taiwan-developed anti-cancer drug-delivery system for phase I clinical study

  • Date: 2021-03-15
  • Update: 2021-03-15
  • Source: 國家衛生研究院
  • Views: 655

US FDA approves Taiwan-developed anti-cancer drug-delivery system for phase I clinical study

March 15, 2021

DBPR115, a small molecule drug conjugate developed in Taiwan by the National Health Research Institutes’ Institute of Biotechnology and Pharmaceutical Research (IBPR) and by Taivex Therapeutics, had its investigational new drug application approved on January 15, 2021, by the U.S. Food and Drug Administration for initiation of a phase I clinical study. This will be an open-label, dose-finding clinical study to assess the safety, pharmacokinetics, and efficacy of DBPR115 in patients. The primary objectives are twofold: (1) to determine the maximum tolerated dose and the recommended phase 2 dose and (2) to characterize the pharmacokinetic and safety profiles of DBPR115 in patients. In addition, the tolerability and preliminary antitumor activity of DBPR115 will also be assessed.

IBPR’s initial research for a novel anti-cancer drug-delivery system was funded by the Ministry of Economic Affairs. DBPR115 was selected as a developmental candidate and its technology transferred to Taivex Therapeutics in August 2016. The technical highlight of DBPR115 is the conjugation of Zn(II)-dipicolylamine (Zn-DPA) to the anti-cancer drug through a proprietary linker design. This patented platform provides a substantial increase of drug concentration at targeted tumor sites, increases the therapeutic index of anti-cancer drugs, reduces drug dosage, and subsequently lessens the adverse effects induced by the drug. Patent protections have been filed in several territories; the US patent was issued in July 2016.

About IBPR

The National Health Research Institutes’ IBPR is a mission-driven drug discovery and development engine (as a project initiator, accelerator, and developer) with vertical and horizontal coordination and integration. Among its goals are to elevate its research capability and be recognized as the center of excellence for innovative drug discovery in Asia.

For more information about IBPR, visit

For more information about this press release, contact Ms. Pey-Yea Yang at +886-37-206-166 ext. 35705; email:

Related photos